Biomarkers of Myocardial Injury and Remodeling in Heart Failure

28Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

With its complicated pathophysiology, high incidence and prevalence, heart failure remains a major public concern. In hopes of improving diagnosis, treatment and prognosis, the utility of many different biomarkers is researched vigorously around the world. In this review, biomarkers of myocardial remodeling and fibrosis (galectin-3, soluble isoform of suppression of tumorigenicity 2, matrix metalloproteinases, osteopontin, interleukin-6, syndecan-4, myostatin, procollagen type I C-terminal propeptide, procollagen type III N-terminal propeptide, vascular endothelial growth factor, nitric oxidase synthetase and asymmetric dimethylarginine), myocyte injury (heart-type fatty acid-binding protein, glutathione S-transferase P1 and heat shock protein 60), as well as iron metabolism (ferritin, transferrin saturation, soluble transferrin receptor and hepcidin), are considered in terms of possible clinical applicability and significance. Our short review consists of a summary of the aforementioned cardiovascular biomarkers’ clinical relevance and perspectives.

Cite

CITATION STYLE

APA

Ponikowska, B., Iwanek, G., Zdanowicz, A., Urban, S., Zymliński, R., Ponikowski, P., & Biegus, J. (2022, May 1). Biomarkers of Myocardial Injury and Remodeling in Heart Failure. Journal of Personalized Medicine. MDPI. https://doi.org/10.3390/jpm12050799

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free